Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kura Oncology (KURA) Shares Outstanding (Diluted Average) (2022 - 2026)

Kura Oncology has reported Shares Outstanding (Diluted Average) over the past 5 years, most recently at $88.6 million for Q1 2026.

  • Quarterly Shares Outstanding (Diluted Average) rose 1.37% to $88.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $88.6 million through Mar 2026, up 1.37% year-over-year, with the annual reading at $87.7 million for FY2025, 1.76% up from the prior year.
  • Shares Outstanding (Diluted Average) was $88.6 million for Q1 2026 at Kura Oncology, up from $87.7 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $88.6 million in Q1 2026 and troughed at $67.0 million in Q4 2022.
  • The 5-year median for Shares Outstanding (Diluted Average) is $86.4 million (2024), against an average of $81.3 million.
  • Year-over-year, Shares Outstanding (Diluted Average) grew 24.13% in 2024 and then increased 0.8% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $67.0 million in 2022, then grew by 9.31% to $73.2 million in 2023, then increased by 17.66% to $86.2 million in 2024, then grew by 1.76% to $87.7 million in 2025, then increased by 1.07% to $88.6 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Shares Outstanding (Diluted Average) are $88.6 million (Q1 2026), $87.7 million (Q4 2025), and $87.6 million (Q3 2025).